Specifically, FBP1 inhibits the potential Warburg effect by counteracting glycolytic flux in clear cell renal cell carcinoma [7], breast cancer [8–10], lung adenocarcinoma [11, 12], hepatocellular carcinoma [13, 14], and prostate cancer [15]. Here, FBP1 is linked to lung adenocarcinoma.